Supplementary Table 1. Week 52 efficacy by treatment dose and for all patients by subgroup analysis in patients who escalated to blinded weekly dosing.

|  |  |  |  |
| --- | --- | --- | --- |
|  | LD ADA | HD ADA | All Patients |
| **Remission, n/N (%)** |  |  |  |
|  BL PCDAI < 40 | 4/18 (22.2) | 5/14 (35.7) | 9/32 (28.1) |
|  BL PCDAI ≥ 40 | 5/30 (16.7) | 6/21 (28.6) | 11/51 (21.6) |
|  BL IMM use | 5/26 (19.2) | 7/18 (38.9) | 12/44 (27.3) |
|  No BL IMM use | 4/22 (18.2) | 4/17 (23.5) | 8/39 (20.5) |
|  BL CS use | 3/19 (15.8) | 4/14 (28.6) | 7/33 (21.2) |
|  No BL CS use | 6/29 (20.7) | 7/21 (33.3) | 13/50 (26.0) |
|  Male | 6/27 (22.2) | 4/18 (22.2) | 10/45 (22.2) |
|  Female | 3/21 (14.3) | 7/17 (41.2) | 10/38 (26.3) |
| **Response, n/N (%)** |  |  |  |
|  BL PCDAI < 40 | 10/18 (55.6) | 10/14 (71.4) | 20/32 (62.5) |
|  BL PCDAI ≥ 40 | 13/30 (43.3) | 10/21 (47.6) | 23/51 (45.1) |
|  BL IMM use | 17/26 (65.4) | 11/18 (61.1) | 28/44 (63.6)\* |
|  No BL IMM use | 6/22 (27.3) | 9/17 (52.9) | 15/39 (38.5) |
|  BL CS use | 8/19 (42.1) | 8/14 (57.1) | 16/33 (48.5) |
|  No BL CS use | 15/29 (51.7) | 12/21 (57.1) | 27/50 (54.0) |
|  Male | 14/27 (51.9) | 8/18 (44.4) | 22/45 (48.9) |
|  Female | 9/21 (42.9) | 12/17 (70.6) | 21/38 (55.3) |

IFX, infliximab; BL, baseline; IMM, immunomodulator; CS, corticosteroid.

\*p<0.05 Chi-square test BL IMM use vs no BL IMM use